Gain Therapeutics (GANX) Institutional Ownership $1.81 -0.10 (-5.24%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$1.81 0.00 (0.00%) As of 05/21/2025 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Gain Therapeutics (NASDAQ:GANX)CurrentInstitutional OwnershipPercentage11.97%Number ofInstitutional Buyers(last 12 months)12TotalInstitutional Inflows(last 12 months)$1.58MNumber ofInstitutional Sellers(last 12 months)2TotalInstitutional Outflows(last 12 months)$390.93K Get GANX Insider Trade Alerts Want to know when executives and insiders are buying or selling Gain Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data GANX Institutional Buying and Selling by Quarter Gain Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/13/2025 Kovitz Investment Group Partners LLC47,578$91K0.0%N/A0.162% 5/7/2025 Dauntless Investment Group LLC125,584$240K0.3%N/A0.427% 2/17/2025 Gotham Asset Management LLC158,155$342K0.0%-52.7%0.596% 2/17/2025 Bridgeway Capital Management LLC30,004$65K0.0%N/A0.113% 2/14/2025 Northern Trust Corp84,586$183K0.0%+88.2%0.319% 2/13/2025 Marshall Wace LLP91,738$198K0.0%N/A0.346% 2/12/2025 Geode Capital Management LLC267,421$578K0.0%-1.7%1.008% 2/6/2025 Jones Financial Companies Lllp98,250$212K0.0%+83.6%0.370% 2/4/2025 Sprott Inc.14,000$30K0.0%N/A0.053% 1/28/2025 Benedict Financial Advisors Inc.16,000$35K0.0%N/A0.060% Get the Latest News and Ratings for GANX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Gain Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/16/2024 Geode Capital Management LLC271,972$484K0.0%+48.0%1.065% 8/9/2024 Renaissance Technologies LLC118,700$152K0.0%+154.2%0.658% 8/9/2024 Warberg Asset Management LLC51,600$66K0.0%N/A0.286% 8/3/2024 Hohimer Wealth Management LLC330,000$422K0.1%N/A1.828% 1/16/2024Raymond James & Associates23,788$78K0.0%-29.6%0.184% 7/25/2023Raymond James & Associates33,400$150K0.0%+67.0%0.271% 5/8/2023 CM Management LLC90,000$434K0.5%-18.2%0.740% 5/2/2023 Wealth Alliance Advisory Group LLC12,502$60K0.0%-33.3%0.105% 4/14/2023Raymond James & Associates20,000$96K0.0%-16.7%0.168% 2/9/2023 CM Management LLC110,000$344K0.4%-12.0%0.926% 1/17/2023 Wealth Alliance Advisory Group LLC18,751$59K0.0%-25.0%0.158% 11/17/2022Telemetry Investments L.L.C.150,000$489K0.6%-6.3%1.263% 10/25/2022Raymond James & Associates24,000$78K0.0%N/A0.202% 10/12/2022 Wealth Alliance Advisory Group LLC25,000$82K0.0%N/A0.210% 5/9/2022 CM Management LLC125,000$511K0.4%+38.9%1.052% 2/3/2022 Advisor Group Holdings Inc.10,050$54K0.0%N/A0.085% 2/2/2022 CM Management LLC90,000$489K0.4%+39.9%0.758% 11/16/2021Telemetry Investments L.L.C.96,232$716K1.0%+217.7%0.810% 11/15/2021Veritable L.P.25,064$187K0.0%N/A0.211% 11/9/2021 Indie Asset Partners LLC29,652$221K0.2%N/A0.250% 11/8/2021 CM Management LLC64,327$479K0.4%+543.3%0.542% 8/17/2021 Bridgeway Capital Management LLC50,000$501K0.0%N/A0.421% 8/16/2021Telemetry Investments L.L.C.30,293$303K0.4%N/A0.255% 8/11/2021 Banque Cantonale Vaudoise3,000$30K0.0%N/A0.025% 8/10/2021 CM Management LLC10,000$100K0.1%N/A0.084% 5/27/2021 Davidson Kempner Capital Management LP15,000$222K0.0%N/A0.126% 5/19/2021 Worth Venture Partners LLC15,532$232K0.1%N/A0.131% 5/18/2021 Millennium Management LLC14,367$214K0.0%N/A0.121% 5/18/2021Greenlight Capital Inc.546,560$8.16M0.6%N/A4.602% 5/18/2021 Davidson Kempner Capital Management LP15,000$222K0.0%N/A0.126% Elon just did WHAT!? (Ad)As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.Click here to see how to claim your stake before they launch to avoid missing out.5/18/2021 Jane Street Group LLC22,754$339K0.0%N/A0.192% (Data available from 1/1/2016 forward) GANX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of GANX shares? During the previous two years, 14 institutional investors and hedge funds held shares of Gain Therapeutics. The most heavily invested institutionals were Geode Capital Management LLC ($578K), Hohimer Wealth Management LLC ($422K), Gotham Asset Management LLC ($342K), Dauntless Investment Group LLC ($240K), Jones Financial Companies Lllp ($212K), Marshall Wace LLP ($198K), and Northern Trust Corp ($183K).Learn more on GANX's institutional investors. What percentage of Gain Therapeutics stock is owned by institutional investors? 11.97% of Gain Therapeutics stock is owned by institutional investors. Learn more on GANX's institutional investor holdings. Which institutional investors have been buying Gain Therapeutics stock? Of the 13 institutional investors that purchased Gain Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Hohimer Wealth Management LLC ($330K), Dauntless Investment Group LLC ($125.58K), Marshall Wace LLP ($91.74K), Geode Capital Management LLC ($88.24K), Renaissance Technologies LLC ($72K), Warberg Asset Management LLC ($51.60K), and Kovitz Investment Group Partners LLC ($47.58K). How much institutional buying is happening at Gain Therapeutics? Institutional investors have bought a total of 964,532 shares in the last 24 months. This purchase volume represents approximately $1.64M in transactions. Which Gain Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Gain Therapeutics stock in the last 24 months: Gotham Asset Management LLC ($176.44K), Raymond James & Associates ($10.01K), and Geode Capital Management LLC ($4.55K). How much institutional selling is happening at Gain Therapeutics? Institutional investors have sold a total of 191,000 shares in the last 24 months. This volume of shares sold represents approximately $423.62K in transactions. Related Companies ProKidney Major Shareholders Foghorn Therapeutics Major Shareholders Rezolute Major Shareholders Annexon Major Shareholders Nuvectis Pharma Major Shareholders Aardvark Therapeutics Major Shareholders Monopar Therapeutics Major Shareholders Bright Minds Biosciences Major Shareholders Acelyrin Major Shareholders Ocugen Major Shareholders This page (NASDAQ:GANX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery I think Trump’s Treasury Secretary is destroying the stock market on purpose. And no one on Wall Street see...Porter & Company | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gain Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gain Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GANX Stock Free GANX Stock Alerts